

# COPY OF PAPERS ORIGINALLY FILED

#### **CERTIFICATE OF MAILING**

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON

April 15, 2002

E-pariello Paighetain

RECE

APR 2 4 000

TECH CERCITALINA

# 190

Záa

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. FCCC96-11

Applicant:

Tsichlis

Serial No.:

09/202,549

Group Art Unit No.: 1636

Filed:

October 12, 1999

Examiner: Davis K.

For:

Nucleic Acid Molecule For Enhancing Gene Expression

Commissioner for Patents Washington, DC 20231

# **AMENDMENT UNDER 37 CFR § 1.111**

Sir:

This Amendment is responsive to the Office Action dated January 15, 2002 (Paper No. 18) (herein referred to as "Office Action").

The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 and 1.17 which may be required by this paper to Deposit Account No. 18-0586.

### In The Specification:

Please amend the specification as indicated under each of the subheadings below.

# **Priority Claim**

At page 1, please add the following text as a separate paragraph after the title of the invention in the specification

--This application is the United States national stage of International Application No. PCT/US97/10486, filed June 17, 1997, which was published under *PCT Article* 21 (2) in English as International Publication No. WO 97/48720, and which claims benefit of priority of U.S. Provisional Application No. 60/019,808 filed June 17, 1996.-